You are here

Field Portable Mass Spectrometry for Small Molecule Drugs in Clinical Samples

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-19-C-0007
Agency Tracking Number: C181-006-0054
Amount: $149,551.91
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD181-006
Solicitation Number: 18.1
Timeline
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2018-10-15
Award End Date (Contract End Date): 2019-04-14
Small Business Information
5100 Springfield Street Suite 301
Dayton, OH 45431
United States
DUNS: 782766831
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Andrew Debalse
 Research Chemist
 (937) 256-7733
 andrew.deblase@spectralenergies.com
Business Contact
 Dr. Sivaram P. Gogineni
Phone: (937) 266-9570
Email: sivaram.gogineni@spectralenergies.com
Research Institution
N/A
Abstract

We propose a novel two-dimensional mass spectrometry (2D-MS) technique based on ion trap arrays to identify illicit and designer drugs. This approach will give an unprecedented multiplex advantage for miniature mass spectrometry, allowing novice field technicians to rapidly identify drugs affecting the central nervous system based on both the m/z ratio and fragmentation pattern of an ion. Towards this aim, we will develop a proof-of-principles testing platform in Phase I to demonstrate (1) pairing of a 36-element ion trap array with a discontinuous ionization source and paper spray ionization (PSI), (2) control of the secular frequency of an ion by systematically changing the trap geometry, and (3) position-sensitive detection from the ion trap array. The instrument constructed in Phase I will evolve into a 2D-MS prototype instrument in Phase II by using an imaging microchannel plates detector to obtain the full 2D mass spectrum. Because 2D-MS will provide an all-in-one measurement of product ion, precursor ion, and neutral loss scans for all ions simultaneously, a field technician will identify drugs based on a computer automated library analysis of these data. Therefore, our measurement will minimize knowledge, training, and interpretation by the user, as required for FDA approval.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government